The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

A CD38 monoclonal antibody, Sarclisa binds to a specific epitope on the CD38 receptor on myeloma cells, ultimately inducing ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

The BM microenvironment encompasses a wide spectrum of cell types and extracellular matrix proteins, including fibronectin, collagen, laminin and osteopontin. Multistep genetic and ...

are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

bsAbs, bispecific antibodies; CRS, cytokine release syndrome; MM, multiple myeloma. With these points in mind, the research by Sandahl et al 1 is commendable not only in terms of the authors' findings ...